摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-溴吡嗪-2-羧酸 | 937669-80-2

中文名称
3-溴吡嗪-2-羧酸
中文别名
2-溴-3-羧酸吡嗪
英文名称
3-bromopyrazine-2-carboxylic acid
英文别名
——
3-溴吡嗪-2-羧酸化学式
CAS
937669-80-2
化学式
C5H3BrN2O2
mdl
——
分子量
202.995
InChiKey
OBDCBKTUEZPSNQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    341.8±42.0 °C(Predicted)
  • 密度:
    1.940±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.7
  • 重原子数:
    10
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    63.1
  • 氢给体数:
    1
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2933990090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:119ab3d11363f7c1676b5c37a463d928
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-溴吡嗪-2-羧酸三叔丁基膦硫酸三氟化硼四丁基溴化铵 、 palladium diacetate 、 potassium carbonatesodium t-butanolate 作用下, 以 四氢呋喃四氯化碳乙醚二氯甲烷甲苯 为溶剂, 反应 77.0h, 生成
    参考文献:
    名称:
    一类电致发光化合物及其制备方法和应用
    摘要:
    本发明公开了一类电致发光化合物及其制备方法和应用。该化合物具有如下结构:或者其环上的H被Ar取代。通过C‑C偶联或C‑N偶联反应得到。制备得到的化合物含有杂原子,可以提高发光材料的荧光量子产率和载流子传输能力;固态条件下不易结晶;具有较高的热分解温度和较强的抗热能力等优点,应用于发光二极管、有机场效应晶体管、有机太阳能电池、有机激光二极管。
    公开号:
    CN108218891B
  • 作为产物:
    描述:
    甲基-3-溴吡嗪-2-羧酸甲酯 、 sodium hydroxide 作用下, 以 甲醇 为溶剂, 生成 3-溴吡嗪-2-羧酸
    参考文献:
    名称:
    Design, Synthesis, and Antidiabetic Activity of 4-Phenoxynicotinamide and 4-Phenoxypyrimidine-5-carboxamide Derivatives as Potent and Orally Efficacious TGR5 Agonists
    摘要:
    4-Phenoxynicotinamide and 4-phenoxypyrimidine-5-carboxamide derivatives as potent and orally efficacious TGR5 agonists are reported. Several 4-phenoxynicotinamide derivatives were found to activate human and mouse TGR5 (hTGR5 and mTGR5) with EC50 values in the low nanomolar range. Compound 23g, with an EC50 value of 0.72 nM on hTGR5 and an EC50 value of 6.2 nM on mTGR5, was selected for further in vivo efficacy studies. This compound exhibited a significant dose-dependent glucagon-like peptide-1 (GLP-1) secretion effect. A single oral dose of 23g (50 mg/kg) significantly reduced blood glucose levels in db/db mice and caused a 49% reduction in the area under the blood glucose curve (AUC)(0-120) (min) following an oral glucose tolerance test (OGTT) in imprinting control region (ICR) mice. However, 23g stimulated gallbladder filling, which might result in side effects to the gallbladder.
    DOI:
    10.1021/jm301071h
点击查看最新优质反应信息

文献信息

  • [EN] FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS<br/>[FR] DÉRIVÉS D'IMIDAZOLE FUSIONNÉS UTILISÉS EN TANT QU'INHIBITEURS D'IL-17
    申请人:UCB BIOPHARMA SPRL
    公开号:WO2019138017A1
    公开(公告)日:2019-07-18
    A series of substituted fused bicyclic imidazole derivatives, including benzimidazole derivatives and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
    一系列替代的融合双环咪唑衍生物,包括苯并咪唑衍生物及其类似物,作为强效的人IL-17活性调节剂,因此在治疗和/或预防各种人类疾病,包括炎症性和自身免疫性疾病方面具有益处。
  • [EN] BRIDGED DIAZEPANE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS DE DIAZÉPANE PONTÉS UTILES EN TANT QU'ANTAGONISTES DES RÉCEPTEURS D'OREXINE
    申请人:MERCK SHARP & DOHME
    公开号:WO2016085783A1
    公开(公告)日:2016-06-02
    The present invention is directed to bridged diazepane compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
    本发明涉及桥联二氮杂环庚烷化合物,其为俄雷欣受体拮抗剂。本发明还涉及所述化合物在潜在的治疗或预防涉及俄雷欣受体的神经和精神障碍和疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在的预防或治疗涉及俄雷欣受体的疾病中的用途。
  • A New Class of Diaryl Ether Herbicides: Structure–Activity Relationship Studies Enabled by a Rapid Scaffold Hopping Approach
    作者:Christopher A. Kalnmals、Zoltan L. Benko、Adel Hamza、Karla Bravo-Altamirano、Thomas L. Siddall、Moriah Zielinski、Hudson K. Takano、Dilpreet S. Riar、Norbert M. Satchivi、Joshua J. Roth、Jeffrey B. Church
    DOI:10.1021/acs.jafc.3c01285
    日期:2023.11.29
    development of a novel class of diaryl ether herbicides. After the discovery of a phenoxybenzoic acid with modest herbicidal activity, optimization led to several molecules with improved control of broadleaf and grass weeds. To facilitate this process, we first employed a three-step combinatorial approach, then pivoted to a one-step Ullmann-type coupling that provided faster access to new analogs. After determining
    我们报告了一类新型二芳基醚除草剂的开发。在发现具有适度除草活性的苯氧基苯甲酸后,优化产生了几种对阔叶杂草和禾本科杂草具有更好控制效果的分子。为了促进这一过程,我们首先采用三步组合方法,然后转向一步乌尔曼型耦合,以更快地获得新的类似物。在确定我们的基准二芳基醚的主要靶位点是乙酰乳酸合酶(ALS)后,我们进一步利用这种铜催化的方法进行支架跳跃活动,希望发现一种具有较少记录的耐药病例的额外作用模式。我们全面、系统的研究表明,虽然该领域的除草活性似乎与 ALS 抑制完全相关,但我们的分子代表了结构独特的 2 类除草剂。本文描述了导致我们得出这一结论的结构-活性关系。
  • Design, Synthesis, and Antidiabetic Activity of 4-Phenoxynicotinamide and 4-Phenoxypyrimidine-5-carboxamide Derivatives as Potent and Orally Efficacious TGR5 Agonists
    作者:Hongliang Duan、Mengmeng Ning、Xiaoyan Chen、Qingan Zou、Liming Zhang、Ying Feng、Lina Zhang、Ying Leng、Jianhua Shen
    DOI:10.1021/jm301071h
    日期:2012.12.13
    4-Phenoxynicotinamide and 4-phenoxypyrimidine-5-carboxamide derivatives as potent and orally efficacious TGR5 agonists are reported. Several 4-phenoxynicotinamide derivatives were found to activate human and mouse TGR5 (hTGR5 and mTGR5) with EC50 values in the low nanomolar range. Compound 23g, with an EC50 value of 0.72 nM on hTGR5 and an EC50 value of 6.2 nM on mTGR5, was selected for further in vivo efficacy studies. This compound exhibited a significant dose-dependent glucagon-like peptide-1 (GLP-1) secretion effect. A single oral dose of 23g (50 mg/kg) significantly reduced blood glucose levels in db/db mice and caused a 49% reduction in the area under the blood glucose curve (AUC)(0-120) (min) following an oral glucose tolerance test (OGTT) in imprinting control region (ICR) mice. However, 23g stimulated gallbladder filling, which might result in side effects to the gallbladder.
  • 一类电致发光化合物及其制备方法和应用
    申请人:华南协同创新研究院
    公开号:CN108218891B
    公开(公告)日:2020-06-05
    本发明公开了一类电致发光化合物及其制备方法和应用。该化合物具有如下结构:或者其环上的H被Ar取代。通过C‑C偶联或C‑N偶联反应得到。制备得到的化合物含有杂原子,可以提高发光材料的荧光量子产率和载流子传输能力;固态条件下不易结晶;具有较高的热分解温度和较强的抗热能力等优点,应用于发光二极管、有机场效应晶体管、有机太阳能电池、有机激光二极管。
查看更多